Atogepant 60 mg vs rimegepant and galcanezumab for episodic migraine prevention has superior efficacy, with comparable safety ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Chase has announced the bonus 5% cash-back categories for the third quarter of 2025. Q4 categories will be announced on Sep. 15, 2025. January to March: Grocery stores, fitness clubs and gym ...

TMBMKGB-05Y | A complete U.K. 5 Year Gilt bond overview by MarketWatch. View the latest bond prices, bond market news and bond rates.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

You signed in with another tab or window. Reload to refresh your session. You signed out in another tab or window. Reload to refresh your session. You switched accounts on another tab or window.